SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community highlights its multi-year track record and organic growth on the Solana network while actively encouraging others to load their bags. Participants are rallying behind the ticker with memes and dad jokes, emphasizing the project's presence on the Jupiter strict list as a core point of interest.

ETHGas is a Blockspace Infrastructure protocol that decomposes Ethereum blockspace into tradable, composable block units, enabling real‑time block production and laying the foundation for a crypto‑native commodities market for gas. By restructuring gas as a financial primitive, ETHGas unlocks: - Faster block times (sub‑second confirmations vs 12‑second Ethereum blocks) through real‑time sequencing. - A futures/forward market for gas, enabling the creation of a native Ethereum yield curve. - Gas abstraction for end users via the Open Gas Initiative, removing gas volatility and shifting costs to protocols. - Commoditization of blockspace, similar to energy or metals markets in traditional finance.

ETHGas

GWEI is gaining attention as a momentum-driven Ethereum ecosystem token following new listings on major exchanges and growing optimism surrounding upcoming legislative clarity in the crypto sector. Community members are actively discussing its price resilience and staking utility while monitoring broader market catalysts for a potential bull cycle.

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining traction as investors flock to the newly launched, low-cap meme coin, with the community actively rallying to drive growth through social media engagement and trending efforts. Supporters are focused on the developer's commitment to transparency and periodic airdrops as they work to overcome early liquidity hurdles and build momentum on Solana-based platforms.

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

4D Molecular Therapeutics Inc

4D Molecular Therapeutics is generating significant investor attention as the company advances its 4D-150 gene therapy following positive clinical data in diabetic macular edema. While some community members are debating the company's valuation relative to its cash position and clinical timelines, others are closely monitoring high short interest as a potential catalyst for volatility.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is generating significant buzz as investors watch for the privacy-focused token to mirror the upward momentum seen in Zcash, fueled by community excitement over its perceived utility and ongoing integrations. While some participants express frustration with price consolidation, many are actively debating its potential for a bullish breakout as it remains a key watch item for those tracking the privacy coin sector.

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

Orca is seeing massive buying momentum and volatility as traders discuss a potential short squeeze fueled by high short interest and market anticipation of upcoming DAO-led buyback programs. The community is actively debating the token's low circulating supply as a catalyst for potential upside while keeping a close watch on key technical levels.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is attracting intense community attention as traders speculate on the potential passage of the Clarity Act, which proponents believe will solidify the token's status as a digital commodity and unlock its utility for institutional payments. While many users remain optimistic about the project's long-term infrastructure role, the discussion is polarized by deep frustration over prolonged price stagnation, accusations of artificial volume manipulation, and skepticism regarding the timing of enterprise adoption.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

The RAGE crypto community is aggressively promoting its status as a foundational internet meme, emphasizing its restoration of original rage comic tools and domains to drive viral engagement. Investors are heavily focused on building long-term conviction and community-led growth, positioning the asset as an undervalued cultural staple with aspirations to reach major market milestones.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is facing heightened community debate as investors weigh long-term bullish sentiment against ongoing consolidation and frustration over price stagnation. The discourse is fueled by a mix of speculative trading activity and interest in broader crypto market shifts, with many participants actively discussing potential breakout catalysts.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is attracting significant community attention as investors debate its role as a key liquidity hub on the Base ecosystem, with many closely tracking its ongoing revenue generation and supply-reduction efforts. While some discuss the potential for long-term growth driven by institutional interest and upcoming network expansions, others are navigating recent price volatility and debating the merits of accumulation at current levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The change does not legalize marijuana but reduces regulatory hurdles and offers tax relief for licensed operators.</li><li>Trump has earlier framed the move as a step toward supporting medical research, while clarifying that it does not legalize recreational use.</li><li>The DOJ is updating procedures to speed up the rulemaking process needed to move marijuana from Schedule I to Schedule III.</li></ul>Shares of Tilray (TLRY), Canopy Growth (CGC), Aurora Cannabis (ACB), and IGC Pharma Inc (IGC) remained in focus after the U.S. Department of Justice formally moved to reclassify state-licensed medical marijuana as a less dangerous drug, four months after President Donald Trump signed an executive order to shift it from Schedule I to Schedule III.After rallying in the previous session and gaining in pre-market trading on Thursday, the stocks fell in morning trade. At the time of writing, TLRY, CGC, ACB and IGC fell between 2-5%.&nbsp;Meanwhile, AdvisorShares Pure US Cannabis ETF (MSOS) fell 5.5%.<h2 class="st-heading-2">DOJ To Update Rulemaking Processes For Reclassification</h2>While the change does not legalize marijuana, it reduces regulatory hurdles, offers tax relief for licensed operators, and makes research easier. Schedule III drugs are considered to have a moderate to low risk of dependence. Trump has earlier framed the move as a step toward supporting medical research, while clarifying that it does not legalize recreational use.“This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information,”&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.justice.gov/opa/pr/justice-department-places-fda-approved-marijuana-products-and-products-containing-marijuana">said</a> Todd Blanche, acting Attorney General, in a statement.Separately, the Justice Department said it is updating procedures to speed up the rulemaking process needed to move marijuana from Schedule I to Schedule III under the Controlled Substances Act. The move is expected to expand access to medical treatments and support research, while also strengthening the legal framework for medical marijuana programs across dozens of U.S. states.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits for TLRY, CGC, ACB, and IGC turned ‘extremely bullish,’ amid ‘extremely high’ message volumes.One user said, “The weed industry is reborn.”<stembedurl>https://stocktwits.com/Lando_Calrissian/message/651131346</stembedurl>Another user said Tilray will be the “king in the U.S. cannabis market.”<stembedurl>https://stocktwits.com/Rumsen/message/651070434</stembedurl>Meanwhile, shares of nano-cap Akanda Corp. (AKAN)&nbsp;climbed 6% higher,&nbsp;extending a stunning 215% surge from the previous session, with investors and traders debating whether the explosive rally is driven by cannabis reclassification optimism or the stock’s low float.Message volumes on the Stocktwits platform for the stock surged by around 48,000% over a 24-hour period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Legalized Marijuana In Canada (Photo by Lane Turner/The Boston Globe via Getty Images)

TLRY, CGC, ACB, MSOS Pare Early Gains After Marijuana Reclassification: Retail Says ‘Weed Industry Is Reborn’

The U.S. Department of Justice formally moved to reclassify state-licensed medical marijuana as a less dangerous drug, four months after President Donald Trump signed an executive order.

Equity

<ul class="summary-bullets"><li>In December, Trump signed an executive order directing the reclassification of marijuana from a Schedule I to a Schedule III drug in the same category as Tylenol with codeine.</li><li>During a separate Oval Office signing ceremony on psychedelics research earlier this month, Trump directly addressed delays in his own rescheduling directive, saying his administration was “slow-walking.”</li><li>A Schedule I drug classification is reserved for substances deemed to have high abuse potential and no accepted medical use such as heroin and LSD.</li></ul> The Trump administration is reportedly slated to move to reclassify marijuana as soon as Wednesday.Axios <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.axios.com/2026/04/22/trump-marijuana-rule-change">reported</a> of the upcoming move, citing an administration official. &nbsp;Shares of Tilray (TLRY) traded 13% higher at the time of writing. Other publicly traded companies in the space including Aurora Cannabis (ACB), Canopy Growth (CGC), and&nbsp; IGC Pharma Inc (IGC) jumped 10%, 20% and 6%, respectively. AdvisorShares Pure US Cannabis ETF (<a href="https://stocktwits.com/symbol/MSOS">MSOS</a>), meanwhile, rallied 23% higher.In December, Trump signed an executive order directing the reclassification of marijuana from a Schedule I to a Schedule III drug in the same category as Tylenol with codeine. The order directed Attorney General to expedite the federal reclassification process through the Drug Enforcement Administration. Trump framed the move as focused on recognizing legitimate medical uses and accelerating research, while explicitly stating it does not legalize recreational marijuana.During a separate Oval Office signing ceremony on psychedelics research earlier this month, Trump directly addressed delays in his own rescheduling directive, saying his administration was “slow-walking.”A Schedule I drug classification is reserved for substances deemed to have high abuse potential and no accepted medical use such as heroin and LSD.The Trump administration is expected to classify marijuana as a Schedule III substance, indicating that it has a lesser potential for abuse and is allowed for use in specific medical treatments, but can also create risks of physical or psychological dependence.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TLRY and CGC are trending in the ‘extremely bullish’ territory, coupled with ‘high’ message volume.While <a href="https://stocktwits.com/symbol/TLRY">TLRY stock</a> has gained 70% over the past 12 months, <a href="https://stocktwits.com/symbol/CGC">CGC</a> has gained 16%.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/rivian-stock-defies-tornado-setback-with-r2-production-kickstart/cZBBvT3ReGy">RIVN Stock Defies Tornado Setback With R2 Production Kickstart</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cannabis plants grow in the greenhouse at Vireo Health's medical marijuana cultivation facility, August 19, 2016 in Johnstown, New York. (Photo by Drew Angerer/Getty Images)

TLRY, CGC, IGC Stocks Light Up On Trump Pot Reclassification Hopes This Week  

Axios reported on Wednesday, citing an administration official, that the Trump administration is slated to reclassify marijuana as soon as Wednesday. 

electroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates

electroCore (ECOR) delivered earnings and revenue surprises of +1.45% and -0.18%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of +180.75% and +147.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Merck KGaA (MKKGY) Lags Q4 Earnings Estimates

Merck KGaA (MKKGY) delivered earnings and revenue surprises of -40.43% and +0.69%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates

IGC Pharma, Inc. (IGC) delivered earnings and revenue surprises of 0.00% and -56.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Profound Medical (PROF) Reports Q3 Loss, Tops Revenue Estimates

Profound Medical (PROF) delivered earnings and revenue surprises of +31.58% and +0.74%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates

Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of +43.48% and -77.27%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of +233.33% and +2.08%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -77.78% and +4.75%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

IGC
IGC Pharma Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IGC News

IGCIGC Pharma Inc